Radiopharm Advances RAD202 to Cohort 4 in Phase 1 HEAT Trial
RADX is trading near its 52-week low of $2.45 (3.3% above the low).
Summary
Radiopharm Theranostics received a DSMC recommendation to advance its RAD202 radiotherapeutic to Cohort 4 (180mCi) in the Phase 1 HEAT trial for HER2-positive solid tumors.
Key Events · Product Development and Regulatory · RADX
-
DSMC Clears Cohort 4 Escalation
Data Safety and Monitoring Committee recommended advancing RAD202 to 180mCi in the Phase 1 HEAT trial for HER2-positive advanced solid tumors.
-
Dose Escalation Progress
Previous dose level of 130mCi was announced on 8 April 2026; the trial is being conducted at clinical centers across Australia.
-
Safety Profile Supported
CEO Riccardo Canevari stated the DSMC recommendation supports the favorable safety profile observed to date and allows continued evaluation of higher dose levels.
-
Clinical Proof-of-Concept
A prior diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution.
Analysis · RADX · Life Sciences
The DSMC's positive recommendation to escalate RAD202 to 180mCi is a meaningful clinical milestone for a company with a thin cash runway. It validates the safety profile at lower doses and keeps the program on track, but it is an incremental step rather than efficacy data. The stock trades near its 52-week low, so positive pipeline news carries extra weight for investor sentiment.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $2.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.1M. The 52-week trading range was $2.45 to $16.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.